

BIOCURE TECHNOLOGY INC.

NOTICE OF CHANGE IN CORPORATE STRUCTURE PURSUANT TO SECTION 4.9 OF NATIONAL INSTRUMENT 51-102 - AMENDED

Item 1. Name and Parties to the Transaction

Biocure Technology Inc. (formerly Gravis Energy Corp.) (the “**Company**”), BiocurePharm Corporation (“**BP Korea**”) and Gravis Energy Korea Corporation (“**Gravis Korea**”)

Item 2. Description of the Transaction

On November 24, 2017, the Company completed the acquisition (the “**Transaction**”) of all of the issued and outstanding shares of BP Korea pursuant to the terms of a merger agreement dated March 22, 2017 (the “**Agreement**”). Pursuant to the Agreement, the Company acquired all of the issued and outstanding securities of BP Korea in consideration of the issuance of common shares of the Company on the basis of 24 post-Consolidation common shares of the Company being issued for each share of BP Korea held. An aggregate of 86,203,968 post-Consolidation common shares were issued pursuant to the Transaction.

The Transaction was effected through a corporate law procedure in Korea whereby the Company incorporated a wholly-owned Korean subsidiary, being Gravis Korea, which initially held the Common Shares issuable to the shareholders of BP Korea. Gravis Korea completed a comprehensive swap procedure with BP Korea in accordance with the Korean Commercial Code such that Gravis Korea ‘swapped’ the common shares issued by the Company for the BP Korea shares and BP Korea became a wholly-owned subsidiary of Gravis Korea, which in turn remains a wholly-owned subsidiary of the Company.

Immediately, prior to the closing of the Transaction, the Company consolidated its common shares on the basis of one (1) post-consolidation common share for 6.033479 pre-consolidation common shares (the “**Consolidation**”) and the Company change its name from “Gravis Energy Corp.” to “Biocure Technology Inc.”

As a result of the completion of the Consolidation and Financing, the Company now has 93,387,632 issued and outstanding common shares.

The common shares of the Company commenced trading on the CSE under its new symbol “CURE”) on November 27, 2017,

Item 3. Effective Date of the Transaction

November 24, 2017

Item 4. Names of Each Party, if any, that Ceased to be a Reporting Issuer Subsequent to the Transaction and of Each Continuing Entity

No party ceased to be a reporting issuer upon completion of the Transaction, and the Company continues as a reporting issuer in the provinces of British Columbia, Alberta and Ontario and the Yukon Territory.

Item 5. Date of the Reporting Issuer's First Financial Year-End Subsequent to the Transaction

The Company's first financial year end subsequent to the completion of the Transaction will be December 31, 2017.

Item 6. The Periods of the Interim and Annual Financial Statements Required to be Filed for the Reporting Issuer's First Financial Year Subsequent to the Transaction

As the Company has adopted a December 31 financial year end, there is no period for which interim financial statements will be filed following the Transaction. The Company's next financial statements will be the audited annual financial statements for the twelve-months ended December 31, 2017, which will be compared to the twelve-month period ended December 31, 2016.

The period for which annual financial statements are required to be filed for the Company's first financial year subsequent to the Transaction is the period from January 1, 2018, being the commencement of the Company's financial year and ended December 31, 2018.

Item 7. Documents filed under NI 51-102 that Describe the Transaction

On March 22, 2017, the Company disseminated and filed on SEDAR a news release announcing the Transaction. On August 30, 2017, the Company disseminated and filed on SEDAR a news release announcing the conditional approval of the CSE for the Transaction. On November 24, 2017, the Company disseminated and filed on SEDAR a news release announcing the completion of the Consolidation and Transaction. The Company also filed on SEDAR, a Listing Statement of the Company dated November 22, 2017 in respect of the requalification for listing of its common shares on the CSE and providing the details of the Consolidation and Transaction.

DATED January 12, 2018

BIOCURE TECHNOLOGY INC.

By: "Sang Mok Lee"
Dr. Sang Mok Lee
President Chief Executive Officer and Director